Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441062 · ClinicalTrials.gov registry record · Phase 2
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
A Phase 2 study of Neuroblastoma and Neuroendocrine Tumors, sponsored by Sue O'Dorisio.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT02441062: Completed Phase 2 study of Neuroblastoma and Neuroendocrine Tumors, sponsored by Sue O'Dorisio.
NCT02441062 is a Phase 2 study of Neuroblastoma and Neuroendocrine Tumors that has completed, run by Sue O'Dorisio. The registered enrollment target is 122 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02441062, a Phase 2 study of Neuroblastoma and Neuroendocrine Tumors, has completed, sponsored by Sue O'Dorisio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.
Primary Outcome
Referring physicians will be asked to fill out pre-PET and post-PET scan forms to provide information on the management and treatment strategy of the patient before the PET-CT scan and after the information from the PET-CT study is available. This is the same methodology used in the National Oncologic PET Registry study; change in management strategy criteria are modified for the specific treatment strategies used in NET.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATOC PET/CT
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2015-09 |
| Est. Completion | 2020-01-20 |
| Phase | Phase 2 |
What the finished NCT02441062 record still lists
NCT02441062 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (49% lower).
The record links to 4 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-DOTATOC PET/CT is the first listed.
NCT02441062 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT02441062 about?
NCT02441062 is a clinical study titled "Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors". Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special proced...
What is the current status of trial NCT02441062?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2015-09. Estimated completion is 2020-01-20.
What conditions does trial NCT02441062 study?
This clinical trial studies the following conditions: Neuroblastoma, Neuroendocrine Tumors, Medulloblastoma, Carcinoid Tumors.
What interventions are being tested in trial NCT02441062?
The interventions under investigation include: 68Ga-DOTATOC PET/CT (DRUG).
Who is sponsoring clinical trial NCT02441062?
This trial is sponsored by Sue O'Dorisio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02441062 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02441062's enrollment target sits among peer trials
122 25th of 94 higher than 69 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
- NCT05168163 · 122 participants · Phase 2
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia